Genome Medicine has published the first in a series of articles on “Proteomic applications in medicine”, guest edited by Sabine Bahn and Paul Guest (Cambridge University). The series aims to highlight progress and challenges in using proteomic techniques in order to gain clinical insight into disease establishment, progression, diagnosis and prognosis. Genome Medicine is now accepting research or methodology article submissions for inclusion in the series.
Guest et al. describe the technological advancements allowing biomarker research to move from discovery to validation, and eventually to the clinic in an introductory Editorial to the series. The importance of studying co-morbidities, and co-development of biomarkers with drugs is discussed.
Also in this issue, Stuart Cordwell and colleagues (Sydney University) describe the plethora of post-translational modifications (PTMs) involved in heart disease, and how high-throughput proteomic techniques have enabled their discovery. They further discuss the importance of studying crosstalk between modifications, with the aim of providing targets for disease intervention.
Future issues will see the publication of several more articles highlighting areas of importance in proteomics. Neil Kelleher (Northwestern University) will discuss top-down proteomics, an area highlighted by Section Editor Matthias Schwab in our recent Editorial. Sabine Bahn and colleagues will review recent advances in fluidic biomarker research in neuropsychiatric disorders, Andrew Emili (University of Toronto) will present the case for the more widespread use of model systems in clinical mass-spectrometry based proteomics. John Koomen (Moffitt Cancer Center) will discuss the use of phosphoproteomics to predict drug response , and Thomas Kislinger (University of Toronto) will review recent advances in proteomic studies of prostate cancer. In addition, we will feature a special discussion of the issue surrounding biomarker validation and standardisation moving into the clinic.